SCHEMBL13826300

SCHEMBL13826300

CCc1ccc(NC(=O)C(C)C)c(F)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.55
▸ PKM P14618 2/20 0.50
▸ ALDH1A1 P00352 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ POLB P06746 2/20 0.46
▸ CTDSP1 Q9GZU7 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ MAP2K2 P36507 1/20 0.44
▸ MAP2K1 Q02750 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ FPR2 P25090 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MDM4 O15151 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ ULK1 O75385 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11423498 0.83 PKM (0.51) GAAPKMALDH1A1POLBCTDSP1
SCHEMBL25085625 0.82 HDAC1 (0.55) GAAPKMALDH1A1KDM4EPOLB
SCHEMBL11431322 0.81 PKM (0.50) GAAPKMKDM4EPOLBCTDSP1
SCHEMBL12780368 0.80 RECQL (0.61) GAAPKMALDH1A1KDM4EPOLB
SCHEMBL11426601 0.79 EPHX2 (0.53) PKMPOLBCTDSP1TDP1L3MBTL1
SCHEMBL7230992 0.79 KDM4E (0.51) GAAPKMKDM4EPOLBFPR2
SCHEMBL29344081 0.78 GAA (0.46) GAAPKMKDM4EPOLBL3MBTL1
SCHEMBL13536979 0.78 KDM4E (0.55) GAAPKMKDM4EPOLBCTDSP1
SCHEMBL18119752 0.78 KMT2A (0.56) GAAPKMALDH1A1KDM4ETDP1
SCHEMBL410861 0.78 KDM4E (0.72) GAAALDH1A1KDM4EPOLBCTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2021-06-01 — — US disclosed
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-09-19 — — US disclosed
WO-2012151525-A9 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-12-13 — — WO disclosed
WO-2012151525-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases MAP4K2, MAP3K20, MAP3K1 GAA 3644/4885PKM 353/4885ALDH1A1 2888/4885
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB GAA 1191/4885PKM 516/4885ALDH1A1 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback